5.21
price down icon5.62%   -0.31
after-market アフターアワーズ: 5.38 0.17 +3.26%
loading
前日終値:
$5.52
開ける:
$5.48
24時間の取引高:
1.03M
Relative Volume:
1.05
時価総額:
$371.97M
収益:
-
当期純損益:
$-297.11M
株価収益率:
-1.0039
EPS:
-5.19
ネットキャッシュフロー:
$-216.95M
1週間 パフォーマンス:
-2.43%
1か月 パフォーマンス:
-7.46%
6か月 パフォーマンス:
-67.92%
1年 パフォーマンス:
-51.26%
1日の値動き範囲:
Value
$5.15
$5.91
1週間の範囲:
Value
$5.15
$6.18
52週間の値動き範囲:
Value
$5.15
$19.71

Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile

Name
名前
Phathom Pharmaceuticals Inc
Name
セクター
Healthcare (1189)
Name
電話
(877) 742-8466
Name
住所
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
Name
職員
112
Name
Twitter
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
PHAT's Discussions on Twitter

PHAT を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
PHAT
Phathom Pharmaceuticals Inc
5.21 371.97M 0 -297.11M -216.95M -5.19
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
483.31 124.35B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
684.87 75.07B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
622.61 37.96B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
243.53 31.79B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
BNTX
Biontech Se Adr
111.56 27.34B 3.30B -501.07M 1.03B -2.1146

Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-02-14 開始されました Cantor Fitzgerald Overweight
2024-05-03 開始されました Stifel Buy
2024-01-05 繰り返されました Needham Buy
2023-08-09 開始されました H.C. Wainwright Buy
2023-05-11 アップグレード Evercore ISI In-line → Outperform
2023-03-13 開始されました Craig Hallum Buy
2022-10-21 開始されました Jefferies Buy
2022-05-06 ダウングレード Evercore ISI Outperform → In-line
2021-05-12 アップグレード Goldman Sell → Neutral
2021-02-17 開始されました BMO Capital Markets Outperform
2021-02-02 開始されました Guggenheim Buy
2020-06-26 ダウングレード Goldman Neutral → Sell
2019-11-20 開始されました Evercore ISI Outperform
2019-11-19 開始されました Goldman Neutral
2019-11-19 開始されました Jefferies Buy
2019-11-19 開始されました Needham Buy
すべてを表示

Phathom Pharmaceuticals Inc (PHAT) 最新ニュース

pulisher
03:28 AM

Phathom Pharmaceuticals stock hits 52-week low at $5.21 - Investing.com

03:28 AM
pulisher
Mar 01, 2025

(PHAT) Investment Analysis and Advice - Stock Traders Daily

Mar 01, 2025
pulisher
Feb 28, 2025

Phathom Pharmaceuticals (PHAT) Expected to Announce Earnings on Thursday - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Cantor Fitzgerald Upgrades Phathom Pharmaceuticals (NASDAQ:PHAT) to Strong-Buy - MarketBeat

Feb 28, 2025
pulisher
Feb 27, 2025

Phathom Pharmaceuticals (PHAT) Projected to Post Quarterly Earnings on Thursday - Defense World

Feb 27, 2025
pulisher
Feb 25, 2025

Phathom Pharmaceuticals to Report Fourth Quarter and Full - GlobeNewswire

Feb 25, 2025
pulisher
Feb 24, 2025

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025 - The Manila Times

Feb 24, 2025
pulisher
Feb 24, 2025

Phathom Pharmaceuticals to Host Conference Call on March 6, 2025, for Fourth Quarter and Full Year 2024 Financial Results - Nasdaq

Feb 24, 2025
pulisher
Feb 24, 2025

Can Phathom's VOQUEZNA Sales Drive Q4 Growth? Earnings Call Set for March 6 - StockTitan

Feb 24, 2025
pulisher
Feb 18, 2025

How to Take Advantage of moves in (PHAT) - Stock Traders Daily

Feb 18, 2025
pulisher
Feb 18, 2025

Phathom Pharmaceuticals CFO Molly Henderson sells shares worth $43,370 - MSN

Feb 18, 2025
pulisher
Feb 18, 2025

Cantor Fitzgerald Begins Coverage on Phathom Pharmaceuticals (NASDAQ:PHAT) - MarketBeat

Feb 18, 2025
pulisher
Feb 17, 2025

Phathom spikes as Cantor Fitzgerald bullish on IP claims - MSN

Feb 17, 2025
pulisher
Feb 16, 2025

Cantor Fitzgerald Initiates Coverage on Phathom Pharmaceuticals (NASDAQ:PHAT) - Defense World

Feb 16, 2025
pulisher
Feb 14, 2025

Phathom stock gains after Cantor bullish view (PHAT:NASDAQ) - Seeking Alpha

Feb 14, 2025
pulisher
Feb 14, 2025

symbol__ Stock Quote Price and Forecast - CNN

Feb 14, 2025
pulisher
Feb 14, 2025

Phathom Pharmaceuticals initiated at Cantor Fitzgerald on ‘significant’ upside - TipRanks

Feb 14, 2025
pulisher
Feb 14, 2025

Cantor Fitzgerald Initiates Coverage on Phathom Pharmaceuticals With Overweight Rating, $23 Price Target - Marketscreener.com

Feb 14, 2025
pulisher
Feb 10, 2025

Taking a Closer Look At Phathom Pharmaceuticals Inc (PHAT) Following Its Recent Trade - Knox Daily

Feb 10, 2025
pulisher
Feb 10, 2025

Phathom Pharmaceuticals (PHAT) Stock Price, News & Analysis - MarketBeat

Feb 10, 2025
pulisher
Feb 09, 2025

Stifel maintains $28 target on Phathom Pharmaceuticals stock - MSN

Feb 09, 2025
pulisher
Feb 08, 2025

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Shares Bought by Jennison Associates LLC - MarketBeat

Feb 08, 2025
pulisher
Feb 07, 2025

Stifel maintains $28 target on Phathom Pharmaceuticals stock By Investing.com - Investing.com Canada

Feb 07, 2025
pulisher
Feb 07, 2025

Phathom Pharmaceuticals Inc (PHAT) Stock: Assessing the Risk and Reward - The News Heater

Feb 07, 2025
pulisher
Feb 07, 2025

The Future of Phathom Pharmaceuticals Inc: Analyzing PHAT - The InvestChronicle

Feb 07, 2025
pulisher
Feb 05, 2025

Phathom Pharmaceuticals Inc [PHAT] CFO and CBO makes an insider sale of 6,583 shares worth $43371.0. - Knox Daily

Feb 05, 2025
pulisher
Feb 04, 2025

Closing Strong: Phathom Pharmaceuticals Inc (PHAT) Ends at 5.63, Down -6.01 from Last Close - The Dwinnex

Feb 04, 2025
pulisher
Feb 04, 2025

A stock that deserves closer examination: Phathom Pharmaceuticals Inc (PHAT) - US Post News

Feb 04, 2025
pulisher
Jan 31, 2025

PHAT stock touches 52-week low at $6.06 amid market challenges - MSN

Jan 31, 2025
pulisher
Jan 31, 2025

Further weakness as Phathom Pharmaceuticals (NASDAQ:PHAT) drops 12% this week, taking five-year losses to 81% - Simply Wall St

Jan 31, 2025
pulisher
Jan 29, 2025

Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference - GlobeNewswire

Jan 29, 2025
pulisher
Jan 29, 2025

Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference - GlobeNewswire Inc.

Jan 29, 2025
pulisher
Jan 29, 2025

Exclusive: Phathom's Next-Gen GI Treatments Take Center Stage at Major Biotech Conference - StockTitan

Jan 29, 2025
pulisher
Jan 27, 2025

Trading (PHAT) With Integrated Risk Controls - Stock Traders Daily

Jan 27, 2025
pulisher
Jan 26, 2025

Phathom Pharmaceuticals Stock: A Comprehensive Analysis of Recent Developments - The Digital Weekly

Jan 26, 2025
pulisher
Jan 24, 2025

Insider Selling: Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) COO Sells 7,886 Shares of Stock - MarketBeat

Jan 24, 2025
pulisher
Jan 24, 2025

Insider Selling: Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) CFO Sells 6,583 Shares of Stock - MarketBeat

Jan 24, 2025
pulisher
Jan 24, 2025

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Insider Terrie Curran Sells 19,109 Shares - MarketBeat

Jan 24, 2025
pulisher
Jan 24, 2025

Phathom Pharmaceuticals COO Nabulsi sells $51,956 in stock By Investing.com - Investing.com South Africa

Jan 24, 2025
pulisher
Jan 23, 2025

Phathom Pharmaceuticals COO Nabulsi sells $51,956 in stock - MSN

Jan 23, 2025
pulisher
Jan 19, 2025

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT): Are Analysts Optimistic? - Yahoo Finance

Jan 19, 2025
pulisher
Jan 17, 2025

(PHAT) Technical Pivots with Risk Controls - Stock Traders Daily

Jan 17, 2025
pulisher
Jan 15, 2025

Barclays PLC Buys 45,402 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World

Jan 15, 2025
pulisher
Jan 12, 2025

Phathom Pharmaceuticals (NASDAQ:PHAT) Earns Buy Rating from Needham & Company LLC - Defense World

Jan 12, 2025

Phathom Pharmaceuticals Inc (PHAT) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Phathom Pharmaceuticals Inc (PHAT) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Nabulsi Azmi
Chief Operating Officer
Jan 21 '25
Sale
6.59
7,886
51,957
233,390
Curran Terrie
President and Chief Executive
Jan 21 '25
Sale
6.59
19,109
125,884
360,465
Nabulsi Azmi
Chief Operating Officer
Dec 19 '24
Sale
8.00
1,118
8,944
239,303
Henderson Molly
CFO and CBO
Dec 19 '24
Sale
8.00
1,291
10,328
98,156
KARBE FRANK
Director
Dec 13 '24
Buy
7.93
12,500
99,084
57,000
Parikh Asit
Director
Dec 13 '24
Buy
8.12
10,000
81,248
75,500
Nabulsi Azmi
Chief Operating Officer
Jul 15 '24
Sale
11.72
10,901
127,760
240,421
Henderson Molly
CFO and CBO
Jul 15 '24
Sale
11.72
4,325
50,689
99,447
Curran Terrie
President and Chief Executive
Jul 15 '24
Sale
11.72
33,848
396,699
377,734
Henderson Molly
CFO and CBO
Apr 08 '24
Sale
11.10
3,435
38,128
95,263
$76.29
price down icon 6.45%
$22.96
price up icon 1.23%
$33.86
price up icon 0.65%
$19.13
price down icon 7.54%
biotechnology ONC
$245.53
price down icon 9.67%
$111.56
price down icon 1.20%
大文字化:     |  ボリューム (24 時間):